These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36920381)

  • 1. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
    Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
    Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 6. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram to Predict Tube Occlusion During Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei.
    Liu Q; Li C; Wang B; Yu G
    J Coll Physicians Surg Pak; 2024 Jul; 34(7):790-794. PubMed ID: 38978242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
    Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
    World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
    Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
    Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 12. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
    Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
    Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing Recurrent Pseudomyxoma Peritonei in 430 Patients After Complete Cytoreduction and HIPEC: A Dilemma for Patients and Surgeons.
    Ahmadi N; Kostadinov D; Sakata S; Ball WR; Gandhi J; Carr NJ; Tzivanakis A; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Ann Surg Oncol; 2021 Nov; 28(12):7809-7820. PubMed ID: 34041626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
    Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A
    J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
    López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
    Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
    Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
    Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
    [No Abstract]   [Full Text] [Related]  

  • 19. Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC.
    Martín Román L; Lozano P; Baratti D; Kusamura S; Deraco M; Vásquez W; González Bayón L
    Ann Surg Oncol; 2022 Nov; 29(12):7553-7563. PubMed ID: 35876926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
    Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
    J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.